Receive our newsletter – data, insights and analysis delivered to you
  1. News
  2. Company News
January 21, 2019

AgeneBio enrols first patient in Phase III trial of AGB101

AgeneBio has enrolled the first patient in the Phase III HOPE4MCI clinical trial to investigate the efficacy of AGB101 for the treatment of amnestic mild cognitive impairment due to Alzheimer's disease (MCI due to AD).

AgeneBio has enrolled the first patient in the Phase III HOPE4MCI clinical trial to investigate the efficacy of AGB101 for the treatment of amnestic mild cognitive impairment due to Alzheimer’s disease (MCI due to AD).

The multi-centre, randomised trial aims to include 830 patients in the US, Canada, and Europe.

A sub-study of specialised imaging is included in the trial to observe the pathology in the brain of the patients.

The primary endpoint of the double-blind, placebo-controlled trial is the cognitive and functional efficacy as measured by the Clinical Dementia Rating Scale – Sum of Boxes (CDR-SB).

“We are excited about the potential for this novel therapy to provide hope for millions of people who suffer from amnestic mild cognitive impairment due to Alzheimer’s disease.”

Secondary imaging endpoints comprise the evaluation of neurodegeneration such as structural MRI, Tau PET.

In order to identify the spread of pathology, investigators of the HOPE4MCI trial will use the MK-6240 scanning for tau along with a structural brain analysis.

Content from our partners
Africa’s last mile: Building viable vaccine supply chains
Why this global life sciences COO believes relocation to Charleston, SC, was key to achieving next-level success
Patient-centric pharma logistics: How CRYOPDP delivers hope worldwide

The MK-6240 scanning for tau is developed by Cerveau Technologies, while the structural brain analysis is developed by AgeneBio in partnership with Johns Hopkins Center for Imaging Science.

AgeneBio research and development vice-president Sharon Rosenzweig-Lipson said: “We are pleased to be at the forefront of a new direction in Alzheimer’s disease research moving beyond amyloid directed therapeutics to target the neuronal overactivity that drives downstream pathology and memory impairment.

“Based on our Phase II findings, we are excited about the potential for this novel therapy to provide hope for millions of people who suffer from amnestic mild cognitive impairment due to Alzheimer’s disease with no approved treatment options.”

AgeneBio has primarily developed the AGB101 therapy to target hippocampal overactivity to slow progression and delay the onset of Alzheimer’s dementia.

Related Companies

NEWSLETTER Sign up Tick the boxes of the newsletters you would like to receive. Key drug pipeline and competitive landscape changes based on the latest clinical activity, sent every Tuesday. Curated analysis and data-driven insights on clinical trials strategy and operations, sent every Thursday. The pharmaceutical industry's most comprehensive news and information delivered every month.
I consent to GlobalData UK Limited collecting my details provided via this form in accordance with the Privacy Policy
SUBSCRIBED

THANK YOU